Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hilgeroth

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Mini Reviews in Medicinal Chemistry|October 9, 2002
Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitorsAndreas Hilgeroth
European Journal of Medicinal Chemistry|May 28, 2003
Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitorsAndreas Hilgeroth, Hauke Lilie
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2009
Recent advances in the development of P-gp inhibitorsChristiane Baumert, Andreas Hilgeroth
Mini Reviews in Medicinal Chemistry|November 11, 2008
Recent advances in the development of multi-kinase inhibitorsMartin Krug, Andreas Hilgeroth
Anti-Cancer Agents in Medicinal Chemistry|September 23, 2021
MDR Inhibitors for Anticancer TherapyPeter Werner, Andreas Hilgeroth
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Synthesis and first biological evaluation of 1-aza-9-oxafluorenes as novel lead structures for the development of small-sized cytostaticsKristin Brachwitz, Andreas Hilgeroth
Frontiers in Cellular Neuroscience|December 7, 2013
Recent developments of protein kinase inhibitors as potential AD therapeuticsVolkmar Tell, Andreas Hilgeroth
Journal of Medicinal Chemistry|April 28, 2006
Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cellsMartin Richter, Jósef Molnár, Andreas Hilgeroth
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 4, 2025
Novel Pyrrolopyrimidines as Inhibitors of CLK4 and HER2: Targeting Promising Anticancer PathwaysJonathan Gries, Frank Totzke, Andreas Hilgeroth
Pharmaceuticals (Basel, Switzerland)|July 15, 2020
Novel Nonsymmetrical 1,4-Dihydropyridines as Inhibitors of Nonsymmetrical MRP-Efflux Pumps for Anticancer TherapyDavid Kreutzer, Christoph A Ritter, Andreas Hilgeroth
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Mini Reviews in Medicinal Chemistry|October 9, 2002
Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitorsAndreas Hilgeroth
European Journal of Medicinal Chemistry|May 28, 2003
Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitorsAndreas Hilgeroth, Hauke Lilie
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2009
Recent advances in the development of P-gp inhibitorsChristiane Baumert, Andreas Hilgeroth
Mini Reviews in Medicinal Chemistry|November 11, 2008
Recent advances in the development of multi-kinase inhibitorsMartin Krug, Andreas Hilgeroth
Anti-Cancer Agents in Medicinal Chemistry|September 23, 2021
MDR Inhibitors for Anticancer TherapyPeter Werner, Andreas Hilgeroth
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Synthesis and first biological evaluation of 1-aza-9-oxafluorenes as novel lead structures for the development of small-sized cytostaticsKristin Brachwitz, Andreas Hilgeroth
Frontiers in Cellular Neuroscience|December 7, 2013
Recent developments of protein kinase inhibitors as potential AD therapeuticsVolkmar Tell, Andreas Hilgeroth
Journal of Medicinal Chemistry|April 28, 2006
Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cellsMartin Richter, Jósef Molnár, Andreas Hilgeroth
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 4, 2025
Novel Pyrrolopyrimidines as Inhibitors of CLK4 and HER2: Targeting Promising Anticancer PathwaysJonathan Gries, Frank Totzke, Andreas Hilgeroth
Pharmaceuticals (Basel, Switzerland)|July 15, 2020
Novel Nonsymmetrical 1,4-Dihydropyridines as Inhibitors of Nonsymmetrical MRP-Efflux Pumps for Anticancer TherapyDavid Kreutzer, Christoph A Ritter, Andreas Hilgeroth
Pageof 7